Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Aytu BioPharma Inc.

    NASDAQ: AYTU · Real-Time Price · USD
    2.21
    0.02 (0.91%)
    At close: Aug 15, 2025, 12:49 PM
    0.91%
    Bid 2.19
    Market Cap 13.64M
    Revenue (ttm) 69.22M
    Net Income (ttm) 1.64M
    EPS (ttm) -1.49
    PE Ratio (ttm) -1.48
    Forward PE -3.26
    Analyst Buy
    Ask 2.21
    Volume 15,609
    Avg. Volume (20D) 387,709
    Open 2.18
    Previous Close 2.19
    Day's Range 2.18 - 2.23
    52-Week Range 0.95 - 2.85
    Beta 0.14

    About AYTU

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol AYTU
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for AYTU stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Aytu BioPharma Inc. is scheduled to release its earnings on Sep 25, 2025, during market hours.
    Analysts project revenue of ... Unlock content with Pro Subscription
    2 months ago
    +34.23%
    Aytu BioPharma shares are trading higher after the... Unlock content with Pro Subscription
    3 months ago
    +91.85%
    Aytu BioPharma shares are trading higher after the company reported better-than-expected Q3 financial results.
    news image

    1 month ago · accessnewswire.com

    Aytu BioPharma Appoints Dr. Gerwin Westfield as Senior Vice President of Scientific Affairs to Support Commercialization of EXXUA(TM)

    DENVER, CO / ACCESS Newswire / June 25, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nerv...

    news image

    1 month ago · accessnewswire.com

    Aytu BioPharma Expands and Extends Lending Agreement with Eclipse Following Agreement to Commercialize First-in-Class Antidepressant EXXUA(TM)

    Term loan maturity extended by 12 months to June 2029 Principal balance on term loan expanded to $13.0 million from $11.1 million currently Expanded revolving line of credit facility by $1.5 million E...

    news image

    2 months ago · accessnewswire.com

    Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan

    Gross proceeds from offering total $16.6 million. Financing led by long-term, healthcare-focused institutional investors, including Aytu's largest shareholders Nantahala Capital Management and Stonepi...

    news image

    2 months ago · accessnewswire.com

    Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock

    Nantahala Capital Management, Stonepine Capital Management, Aytu Management, and New Institutional Shareholders Lead Financing. DENVER, CO / ACCESS Newswire / June 6, 2025 / Aytu BioPharma, Inc. (the ...

    news image

    2 months ago · accessnewswire.com

    Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States

    Aytu enters the over $22 billion United States prescription major depressive disorder ("MDD") market with the first-in-class oral selective serotonin 5HT1a receptor agonist for adults with MDD. EXXUA ...

    Add to Watchlist